Brian Cahill - Eagle Pharmaceuticals Chief Officer
| EGRXDelisted Stock | USD 1.99 0.02 1.02% |
Insider
Brian Cahill is Chief Officer of Eagle Pharmaceuticals
| Age | 55 |
| Phone | 201 326 5300 |
| Web | https://www.eagleus.com |
Brian Cahill Latest Insider Activity
Tracking and analyzing the buying and selling activities of Brian Cahill against Eagle Pharmaceuticals pink sheet is an integral part of due diligence when investing in Eagle Pharmaceuticals. Brian Cahill insider activity provides valuable insight into whether Eagle Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Eagle Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eagle Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Brian Cahill over six months ago Disposition of 735 shares by Brian Cahill of Eagle Pharmaceuticals at 5.13 subject to Rule 16b-3 |
Eagle Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.0663 % which means that it generated a profit of $0.0663 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0488 %, meaning that it created $0.0488 on every $100 dollars invested by stockholders. Eagle Pharmaceuticals' management efficiency ratios could be used to measure how well Eagle Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Eagle Pharmaceuticals currently holds 62.47 M in liabilities with Debt to Equity (D/E) ratio of 0.23, which may suggest the company is not taking enough advantage from borrowing. Eagle Pharmaceuticals has a current ratio of 1.74, which is within standard range for the sector. Debt can assist Eagle Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Eagle Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Eagle Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Eagle to invest in growth at high rates of return. When we think about Eagle Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| David Erickson | Evolus Inc | N/A | |
| Ziping Luo | Amphastar P | 74 | |
| Philip Terpolilli | Prestige Brand Holdings | N/A | |
| Jeffrey Zerillo | Prestige Brand Holdings | 63 | |
| Dean Siegal | Prestige Brand Holdings | N/A | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Yongfeng Zhang | Amphastar P | 77 | |
| YatGai Au | Regencell Bioscience Holdings | 51 | |
| Jacob MBA | Amphastar P | 50 | |
| Thomas Harvey | Alkermes Plc | N/A | |
| Damian Finio | Phibro Animal Health | 54 | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Wai Chung | Regencell Bioscience Holdings | 47 | |
| Michelle Chan | Regencell Bioscience Holdings | N/A | |
| Floyd MD | Alkermes Plc | 87 | |
| Scott Gordon | Silver Spike Investment | 63 | |
| Richard MD | Collegium Pharmaceutical | 64 | |
| Adel Mekhail | Prestige Brand Holdings | 63 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Sandra Beaver | Evolus Inc | 46 | |
| Gregory Gentile | Silver Spike Investment | 48 | |
Management Performance
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 |
Eagle Pharmaceuticals Leadership Team
Elected by the shareholders, the Eagle Pharmaceuticals' board of directors comprises two types of representatives: Eagle Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eagle. The board's role is to monitor Eagle Pharmaceuticals' management team and ensure that shareholders' interests are well served. Eagle Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eagle Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Michael Graves, Independent Director | ||
| Debra Hussain, Senior Commercial | ||
| Gaozhong Zhu, Senior Development | ||
| Reiner Nowak, Exec | ||
| Ryan Debski, General VP | ||
| John Kimmet, Ex Care | ||
| Daniel OConnor, Chief VP | ||
| Steven Ratoff, Independent Director | ||
| Scott Tarriff, CEO and President Director and Member of Executive Committee | ||
| Valentin MD, Senior Development | ||
| Brian Cahill, Chief Officer | ||
| Reed McClung, Executive Development |
Eagle Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Eagle Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0488 | ||||
| Return On Asset | 0.0663 | ||||
| Profit Margin | 0.05 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 82.05 M | ||||
| Shares Outstanding | 12.96 M | ||||
| Shares Owned By Insiders | 12.02 % | ||||
| Shares Owned By Institutions | 76.65 % | ||||
| Number Of Shares Shorted | 350.53 K | ||||
| Price To Earning | 40.52 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Stocks Directory module to find actively traded stocks across global markets.
Other Consideration for investing in Eagle Pink Sheet
If you are still planning to invest in Eagle Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Eagle Pharmaceuticals' history and understand the potential risks before investing.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stocks Directory Find actively traded stocks across global markets | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |